FDA Peptide Reclassification 2026: What Actually Changed

Headlines claimed that “peptides are legal again.” The real story is narrower, and it matters if you are a patient, a clinician or a pharmacy.

Background: the 2023 Category 2 list

In late 2023 the FDA put 19 widely used peptides on Category 2 of its interim 503A bulks list, citing immunogenicity, manufacturing impurity risks and thin human clinical data. That effectively stopped licensed compounding pharmacies from preparing them.

What happened in 2026

• February: HHS Secretary Robert F. Kennedy Jr. announced that about 14 of the 19 peptides would move off the restricted list.
• April 15: The FDA announced a meeting of its Pharmacy Compounding Advisory Committee (PCAC) and republished its interim list, indicating removal of 12 peptides from Category 2, effective around April 22.
• July 23-24: The PCAC voted on seven peptide bulk substances and recommended six of them, including BPC-157 (8 to 6, for ulcerative colitis), KPV, TB-500, MOTS-c, Epitalon and Semax. Emideltide (DSIP) was not recommended (6 to 7). The votes are advisory and the FDA still has to act. See our full vote results.
• Before February 2027: A later PCAC meeting is expected to consider five more substances: LL-37, Dihexa acetate, injectable GHK-Cu, PEG-MGF and Melanotan II.

What reclassification does

It governs one thing: whether a licensed 503A pharmacy may compound a substance for a patient who has a valid prescription. Law-firm and pharmacy analyses stress that removal from Category 2 does not by itself establish eligibility for compounding.

What it does not do

• It does not make the peptides FDA-approved drugs.
• It does not mean they are safe or effective for any given use.
• It does not legalize “research use only” products for human use.

Why it matters for readers

Quality depends on the pharmacy, and clinical oversight is essential. Ask a prescriber about sourcing, sterility testing and the evidence for your specific condition.

FAQ

Which peptides were affected?

Reported names include BPC-157, TB-500, thymosin alpha-1, CJC-1295 and ipamorelin. Others, such as GHRP-2 and GHRP-6, were reported as likely to stay restricted.

Is Category 1 the same as approved?

No. Category 1 only means a substance may be compounded under interim policy while the FDA keeps evaluating it.

Sources: Pharmacy Times (June 4, 2026); Goodwin Procter via Mondaq (April 15, 2026); Aesthetics Journal (April 2026); American Med Spa Association (April 16, 2026).

This article is for general news and education. It is not medical or legal advice. Talk to a licensed clinician about any treatment decision.